If Cytodyn releases the info, it will be a press release from a company with a 24 cent share price and a questionable history with the FDA. And a former CEO awaiting sentencing. If EMSO releases the data then we have institutional validity and a boatload of medical professionals and academics who will not only become aware of leronlimab--if they don't know about it already--but who may, if asked by their hometown newspapers, to comment on its potential in controlling metastasis. With the data fresh in their minds.

I'll take the ESMO option.

--Sherlock--